aTyr Pharma to Participate in ROTH Capital Partners Webinar on COVID-19 Therapeutics in Development on October 28th
aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged
in the discovery and development of innovative medicines based on
novel biological pathways, today announced that Sanjay S. Shukla,
M.D., M.S., President and Chief Executive Officer, will participate
in a panel titled, “Immune Modulators to Ameliorate COVID-19” as
part of the ROTH Capital Partners Webinar on COVID-19 Therapeutics
in Development on October 28, 2020.
Details of the event are as follows:
Event: ROTH Capital Partners Webinar on COVID-19
Therapeutics in DevelopmentPanel: Immune Modulators to Ameliorate
COVID-19Date: Wednesday, October 28, 2020Time: 9:00 a.m. – 10:20
a.m. Eastern Time
Registration for the webinar is available on the
Investor’s section of the Company’s website at www.atyrpharma.com.
A replay of the live webcast will be available on the Company’s
website following the event.
aTyr is a biotherapeutics company engaged in the
discovery and development of innovative medicines based on novel
biological pathways. aTyr’s research and development efforts are
concentrated on a newly discovered area of biology, the
extracellular functionality and signaling pathways of tRNA
synthetases. aTyr has built a global intellectual property estate
directed to a potential pipeline of protein compositions derived
from 20 tRNA synthetase genes and their extracellular targets.
aTyr’s primary focus is ATYR1923, a clinical-stage product
candidate which binds to the neuropilin-2 receptor and is designed
to down-regulate immune engagement in inflammatory lung diseases.
For more information, please visit http://www.atyrpharma.com.
Contact:Ashlee DunstonInvestor Relations, aTyr